The distribution of bamlanivimab plus etesevimab was paused in the United States because of the increase in the combined frequencies of the Gamma (P.1) and Beta (B.1.351) SARS-CoV-2 variants of concern circulating across the country. In recent months, the Delta (B.1617.2, non-AY.1/AY.2) variant has become the predominant variant circulating in all states. Because the combination of bamlanivimab plus etesevimab retains activity against the Delta variant, as of September 2, 2021, the use and distribution of these anti-SARS-CoV-2 mAbs have been resumed in all U.S. states, territories, and jurisdictions.

The Panel recommends using one of the following anti-SARS-CoV-2 mAb regimens (listed alphabetically and not in order of preference) to treat nonhospitalized patients with mild to moderate COVID-19 who are at high risk of clinical progression (see Anti-SARS-CoV-2 Monoclonal Antibodies for the rating of the recommendations based on the risk of progression to COVID-19):


Tags: Law, Juggement, lawyer, Cases

Leave a Comment